The TDB of the DST has signed an agreement with Griva Healthcare Pvt. Ltd. to move its indigenous AI‑driven cervical cancer screening device, GrivaVision, from prototype to commercial production in Kerala.
Key Developments
- Manufacturing set up at Kollam, Kerala for large‑scale production.
- Device integrates a high‑definition camera, built‑in display, user‑friendly interface and AI for early detection.
- Complies with WHO‑approved AVE standards and is ABDM-compatible.
- Classified as a Class B device with CDSCO licence and built to ISO 13485 standards.
- More than 50% of components are sourced domestically, strengthening the Indian medical‑device value chain.
Important Facts
GrivaVision is a portable digital colposcope designed to visualise the vaginal canal and detect cervical lesions during routine examinations. The hardware architecture is proprietary and patented in India. R&D is currently carried out at AIC‑AMTZ Medivalley, Visakhapatnam, while the TDB‑supported project will shift production to the new Kerala facility.
India has a large population of women eligible for cervical cancer screening. Early and accessible screening can significantly reduce disease burden, especially in underserved and resource‑constrained regions.
Exam Relevance
Understanding this initiative helps aspirants in multiple GS papers:
- GS3 – Health & Technology: Shows how indigenous innovation, AI, and digital health are being integrated into public health programmes.
- GS3 – Economy: Highlights t